Cargando…
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy
BACKGROUND: Immuno-oncology (I-O) therapies target the host immune system, providing the potential to choose a uniform dose and schedule across tumor types. However, dose selection for I-O agents usually occurs early in clinical development and is typically based on tumor response, which may not ful...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109842/ https://www.ncbi.nlm.nih.gov/pubmed/27879974 http://dx.doi.org/10.1186/s40425-016-0177-2 |